LIVE WEBINAR: CDP/Policy 0070: Key Learnings and Takeaways Since the September 2023 Relaunch. Join us Tuesday, June 04 @10am EST.

REGISTER
X

Advancing Anonymization For Clinical Trial Disclosure.

Real Life Sciences (RLS) protects Personal & Confidential Information utilizing advanced anonymization techniques. Anonymized data allows you to share clinical data and documents with Health Authorities, partners, internal teams and publications with confidence.
Get in touch
Illustration of real world evidence discovery

We Are Real Life Sciences

RLS enables pharmaceutical manufacturers to submit anonymized and redacted clinical data and documents to Health Authorities and disclose trial results with confidence. Navigating the regulatory guidance, requirements and timelines of the various global regulations and policies can be challenging. RLS’ purpose built technology, RLS Protect, combined with its expert global Services team will provide the support and experience you need to be successful.

Anonymization Is Not One Size Fits All

The individual characteristics of your project will have a direct impact on selecting the most appropriate anonymization strategy. For example, a regulatory submission project requiring anonymized personal data such as EMA’s Policy 0070 and Health Canada PRCI are best suited for a quantitative risk-based anonymization strategy. Here, the resulting risk of re identification and data utility can be measured, giving you and the Health Authority confidence in the result. When limited patient level data is applicable, a qualitative or rules based anonymization strategy may be appropriate.

Whether you are planning a regulatory disclosure project, preparing CTR documents for publication or anonymizing a trial dataset for voluntary sharing, RLS will help you determine the most suitable strategy for your project, with consideration of potential downstream re-use of the data for other use cases.

Document & Data Anonymization & Redaction

RLS PROTECT is the leading data and document anonymization and redaction solution designed specifically for Sponsors and CROs who comply with transparency requirements for regulatory bodies and voluntary sharing initiatives. RLS PROTECT offers the most advanced quantitative risk modeling, document anonymization and redaction capabilities enabling your organization to scale and support the increasing demands of Health Canada PRCI, EMA Policy 0070, EMA (EU) 536/2014, FDA as well as data sharing partners supporting secondary research.

Visit our European Medicines Agency (EMA) CTR & CTIS Pages:

European Medicines Agency (EMA) Clinical Trial Regulation (CTR) Overview
European Medicines Agency (EMA) Clinical Trials Information System (CTIS) Overview

Learn more About RLS Protect
Doctor with halo of health options

Professional & Experienced

RLS Anonymization Services Logo
Real Life Sciences offers industry leading software-as-a-service technology and operational Anonymization Services to achieve your business needs. Our Anonymization Services team, made up of full-time staff, uses our proprietary tech and a proven methodology every day to deliver anonymization and redaction projects on-time and on-quality for Sponsors and CROs. RLS offers flexible engagement models to align with your priorities and specific needs.
Learn more

Our Clients

Working Together

We work with leading global life sciences companies, industry consortiums, service providers and regulatory organizations.

Let us show you how RLS can help.

Accurate, Efficient and Secure.

Our solutions and services are held to the highest performance and security standards. We are regulator tested , sponsor approved and data secure.
Get in touch

Stay up to date

Gain Insights

Stay informed on the latest real world data and evidence trends or keep up to date on the latest regulatory changes from Health Canada and EMA to stay ahead.
Learn more

Curating Self-Reported Patient & Caregiver Narratives

Natural Language Processing (NLP) algorithms enable us to use novel data sources such as electronic health records (EHR), media interview...
LEARN MORE >

Anonymization Primer: Risk Thresholds for Patient Re-identification

As data sharing becomes the new norm, protecting patient privacy and confidentiality has new challenges. Earlier in clinical trial datasets,...
LEARN MORE >

Maximizing Data Utility In Clinical Disclosure: Reference Populations

Choosing the right reference population maximizes data utility. While choosing the right reference population, the right approaches and methods further...
LEARN MORE >
1 2 3 5
crossmenuchevron-leftchevron-right